Drugs / CELYVIR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01844661 | Jan 2013 → Dec 2014 | cancer, metastatic neoplasm | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Celyvir | “Our group uses mesenchymal stem cells (MSCs) to transport oncolytic adenoviruses (OAds) to the tumor site, a therapeutic strategy called Celyvir.” PMID 33737338 ↗ Mar 2021 |
| Modality | Cell therapy | “Celyvir, an advanced therapy medicine that combines autologous mesenchymal stem cells (MSCs) carrying an oncolytic adenovirus.” PMID 32053771 ↗ Jan 2020 |
| Route | Intravenous | “Celyvir was manufactured from a bone marrow aspirate and then given intravenously.” PMID 32053771 ↗ Jan 2020 |